Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

SNOA · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

1.09USD-0.08 (-6.84%)

Price History

Full chart

Market Stats

Previous Close1.17
Open1.20
Day Range1.08 – 1.20
52-Week Range0.85 – 4.60
Volume94.80K
Market Cap6.08M
P/E (TTM)0.00
Forward P/E46.08
EPS-1.22
Dividend Yield0.00%
Beta1.31
50-Day Avg1.26
200-Day Avg2.02

About

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Amy M. Trombly Esq., J.D.
  • Employees10
  • Headquarters5445 Conestoga Court, Boulder, CO, United States, 80301, USA
  • Websitehttps://sonomapharma.com

Leadership

  • Ms. Amy M. Trombly Esq., J.D.CEO, President & Director · b. 1968
  • Mr. Jerome J. Dvonch CPAChief Financial Officer · b. 1968
  • Mr. Arturo AngelSenior Vice President of Regulatory, Quality & Product Development

Financials

Income Statement

Currency: USD2002-03-312003-03-312004-03-312005-03-312006-03-312007-03-312008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue2.00M2.47M902.00K1.36M2.58M4.54M3.83M5.39M7.36M9.75M12.74M15.45M13.67M13.85M9.37M12.82M16.66M18.97M17.93M18.63M12.63M13.27M12.73M14.29M19.53M
Growth (%)-+23.50%-63.48%+50.33%+90.56%+75.81%-15.58%+40.50%+36.67%+32.46%+30.65%+21.25%-11.55%+1.36%-32.37%+36.89%+29.89%+13.88%-5.49%+3.91%-32.21%+5.10%-4.05%+12.19%+36.68%
Cost of Revenue815.00K1.77M-3.52M4.90M3.00M2.75M2.59M3.49M3.61M4.03M4.71M5.27M6.57M6.72M7.16M9.35M10.09M9.81M12.07M8.63M8.79M7.99M8.82M12.11M
Gross Profit1.19M702.00K902.00K-2.17M-2.32M1.54M1.08M2.80M3.88M6.14M8.71M10.74M8.40M7.29M2.65M5.67M7.31M8.88M8.12M6.56M3.99M4.48M4.75M5.46M7.42M
Gross Margin59.25%28.42%100.00%-159.73%-89.71%33.99%28.27%52.00%52.66%62.96%68.38%69.52%61.44%52.61%28.26%44.19%43.88%46.81%45.30%35.21%31.62%33.73%37.26%38.25%37.97%
Operating Expense1.33M2.17M014.15M18.53M21.03M23.51M20.11M11.89M13.65M15.18M14.12M14.45M13.95M17.36M18.64M21.50M20.14M15.51M10.01M9.88M9.05M9.45M9.18M9.88M
Operating Income-147.00K-1.47M902.00K-16.31M-20.85M-19.48M-22.43M-17.31M-8.02M-7.50M-6.47M-3.37M-6.05M-6.66M-14.71M-12.97M-14.19M-11.26M-7.39M-3.45M-5.89M-4.57M-4.70M-3.71M-2.46M
Operating Margin-7.35%-59.43%100.00%-1202.95%-806.93%-428.88%-584.75%-321.21%-108.85%-76.94%-50.75%-21.84%-44.27%-48.07%-157.05%-101.16%-85.18%-59.35%-41.22%-18.51%-46.62%-34.43%-36.91%-25.97%-12.60%
EBITDA-147.00K-1.47M1.06M-15.88M-20.20M-18.81M-21.68M-16.54M-7.58M-7.11M-6.07M-4.06M5.08M-7.95M-14.48M-12.69M-13.75M-10.85M-3.22M-3.22M-5.22M-5.06M-4.86M-2.77M-2.32M
EBITDA Margin-7.35%-59.43%117.74%-1170.94%-781.73%-414.09%-565.45%-306.96%-102.97%-72.89%-47.65%-26.25%37.15%-57.36%-154.52%-98.92%-82.53%-57.22%-17.94%-17.30%-41.35%-38.12%-38.12%-19.38%-11.89%
Net Income-167.00K-1.59M-7.30M-16.53M-23.10M-19.78M-20.34M-17.66M-8.23M-7.95M-7.33M-5.43M3.73M-8.20M-10.16M9.27M-14.33M-11.80M-3.31M-3.95M-5.09M-5.15M-4.83M-3.46M-3.17M
Net Income Margin-8.35%-64.57%-809.09%-1219.03%-893.92%-435.46%-530.35%-327.69%-111.79%-81.48%-57.51%-35.15%27.33%-59.21%-108.46%72.31%-86.01%-62.19%-18.45%-21.20%-40.28%-38.81%-37.97%-24.20%-16.26%
R&D6.00K68.00K-1.65M2.60M4.51M9.78M6.25M2.00M2.05M1.98M2.22M2.89M1.53M1.81M1.58M1.57M1.52M1.34M555.00K125.00K207.00K1.87M1.81M2.27M
R&D as % of Total Revenue0.30%2.75%-121.98%100.62%99.23%254.97%116.04%27.10%20.98%15.54%14.39%21.12%11.07%19.28%12.29%9.45%8.00%7.47%2.98%0.99%1.56%14.69%12.70%11.63%
Interest Expense000372.00K172.00K956.00K1.02M437.00K9.00K406.00K931.00K1.11M1.06M3.00K3.00K3.00K40.00K33.00K16.00K12.00K10.00K16.00K---
Interest Expense % of Total Revenue0.00%0.00%0.00%27.43%6.66%21.04%26.49%8.11%0.12%4.16%7.31%7.16%7.74%0.02%0.03%0.02%0.24%0.17%0.09%0.06%0.08%0.12%---

Balance Sheet

Currency: USD2002-03-312003-03-312004-03-312005-03-312006-03-312007-03-312008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets1.69M961.00K-6.94M12.69M26.95M23.61M5.45M10.22M8.66M7.84M12.56M20.79M15.05M13.80M25.46M19.21M14.45M14.56M14.99M18.84M16.23M14.74M13.69M13.96M
Total Liabilities-1.04M-4.74M5.35M12.05M8.18M3.18M3.17M6.96M8.71M8.48M8.73M2.99M3.66M4.03M3.88M3.96M8.94M9.62M10.15M8.25M8.60M9.28M10.87M
Total Equity940.00K-79.00K-2.20M7.34M14.90M15.43M2.27M7.04M1.70M-868.00K4.08M12.06M12.05M10.14M21.43M15.33M10.49M5.62M5.36M8.70M7.98M6.14M4.41M3.10M
Cash764.00K177.00K-3.29M7.45M19.05M18.82M1.92M6.26M4.37M3.35M7.90M5.48M6.14M7.47M17.46M10.07M3.69M3.69M4.22M7.40M3.82M3.13M5.37M2.40M
Total Debt---1.50M770.00K8.08M2.22M335.00K314.00K2.54M3.24M1.94M147.00K87.00K114.00K410.00K553.00K475.00K850.00K2.67M1.37M849.00K608.00K305.00K842.00K
Net Debt-764.00K-177.00K--1.79M-6.68M-10.97M-16.60M-1.59M-5.94M-1.83M-112.00K-5.96M-5.33M-6.05M-7.36M-17.05M-9.51M-3.21M-2.84M-1.54M-6.03M-2.97M-2.52M-5.07M-1.56M

Cash Flow

Currency: USD2004-03-312005-03-312006-03-312007-03-312008-03-312009-03-312010-03-312011-03-312012-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-5.56M-13.53M-20.52M-18.08M-17.45M-16.83M-6.64M-4.43M-4.03M1.15M-4.89M-6.69M-8.75M-8.17M-12.44M-11.72M-4.59M-3.38M-4.25M-6.15M-2.40M-88.00K-3.93M
Investing Cash Flow-1.01M-1.12M-1.58M-877.00K-617.00K-424.00K-184.00K-164.00K-360.00K-370.00K-445.00K875.00K4.19M18.22M-201.00K-131.00K3.64M388.00K-99.00K-258.00K-2.00K-80.00K-192.00K
Financing Cash Flow7.27M17.20M26.12M30.57M17.83M376.00K11.08M2.68M3.45M3.75M2.94M6.61M6.04M-32.00K5.24M5.49M1.03M3.31M7.40M2.49M1.68M3.03M477.00K
Capital Expenditure980.00K1.04M475.00K873.00K617.00K393.00K141.00K174.00K336.00K257.00K504.00K139.00K345.00K394.00K187.00K100.00K206.00K179.00K137.00K269.00K17.00K80.00K192.00K
Free Cash Flow-6.54M-14.57M-21.00M-18.95M-18.06M-17.23M-6.78M-4.60M-4.37M893.00K-5.39M-6.83M-9.09M-8.56M-12.63M-11.82M-4.80M-3.56M-4.38M-6.42M-2.42M-168.00K-4.13M
Dividends Paid--------02.56M06.53M6.14M00--------
FCF to OCF117.63%107.70%102.31%104.83%103.54%102.33%102.12%103.93%108.33%77.65%110.31%102.08%103.94%104.82%101.50%100.85%104.49%105.30%103.23%104.37%100.71%190.91%104.88%
Dividend Paid to FCF--------0.00%287.23%0.00%-95.61%-67.58%0.00%0.00%--------

Earnings

Report DateFeb 22, 2007Jun 7, 2007Aug 9, 2007Nov 12, 2007Feb 7, 2008Jun 11, 2008Aug 5, 2008Nov 6, 2008Feb 13, 2009Jun 12, 2009Aug 7, 2009Nov 5, 2009Feb 4, 2010Jun 3, 2010Aug 5, 2010Nov 4, 2010Feb 3, 2011Jun 2, 2011Aug 4, 2011Nov 3, 2011Feb 2, 2012Jun 7, 2012Aug 2, 2012Nov 1, 2012Feb 13, 2013Jun 13, 2013Aug 8, 2013Nov 19, 2013Feb 13, 2014Jun 12, 2014Aug 7, 2014Nov 13, 2014Feb 12, 2015Jun 11, 2015Jul 30, 2015Nov 5, 2015Feb 4, 2016Jun 16, 2016Jul 28, 2016Nov 10, 2016Feb 9, 2017Jun 5, 2017Aug 8, 2017Nov 9, 2017Feb 7, 2018Jun 13, 2018Aug 8, 2018Nov 8, 2018Feb 14, 2019Jun 30, 2019Aug 13, 2019Nov 14, 2019Feb 14, 2020Jun 30, 2020Aug 14, 2020Nov 20, 2020Feb 16, 2021Jun 30, 2021Aug 16, 2021Nov 15, 2021Feb 11, 2022Aug 11, 2022Nov 14, 2022Feb 14, 2023Jun 21, 2023Aug 10, 2023Nov 13, 2023Feb 8, 2024Jun 17, 2024Aug 8, 2024Nov 7, 2024Feb 5, 2025Jun 17, 2025Aug 7, 2025Nov 4, 2025Feb 10, 2026Jun 16, 2026Aug 6, 2026Nov 3, 2026
EPS Estimate--129.15-2961.00-2835.00-2709.00-124.43-2058.00-2520.00----630.00-441.00-252.00-22.05-567.00-441.00-23.10-378.00-346.50-315.00-23.62-315.00189.00-168.00-6.00-193.50-135.00-126.00-9.22-153.00-171.00-162.00-11.25-63.00-72.00-81.00-0.11-99.00-106.20554.40-6.03-131.40-124.20-111.00-5.28-95.40-81.90-60.30-2.12-35.80-23.60-0.72--0.91-1.18-0.720.00------0.62-0.23-0.12-4.80-4.20-0.17-0.80-0.80-0.60-0.04-0.51-0.31-0.29---
EPS Actual-7381.58-166.95-2646.00-2772.00-2520.00-107.10-2079.00-2709.00-1313.49-756.00-1150.62-630.00-315.00-378.00-28.35-441.00-504.00-15.75-535.50-189.00-630.00-15.75-371.70-216.72-169.28-10.35-190.80-203.31-287.84-12.60-9.00-72.00-621.0010.80-108.00-70.65-134.18-0.80-92.52-63.72736.56-5.13-147.60-120.60-131.40-8.37-99.00-79.20-46.80-1.52-26.70-18.2012.72-0.390.540.06-0.32-0.52-0.52-0.04-0.31-0.29-0.33-0.62-0.31-0.28-5.80-1.60-0.07-1.40-0.59-0.63-0.48-0.37-0.32-0.48-0.150.02-
Surprise--29.27%10.64%2.22%6.98%13.93%-1.02%-7.50%---0.00%28.57%-50.00%-28.57%22.22%-14.29%31.82%-41.67%45.45%-100.00%33.32%-18.00%-214.67%-0.76%-72.50%1.40%-50.60%-128.44%-36.66%94.12%57.89%-283.33%196.00%-71.43%1.88%-65.65%-627.27%6.55%40.00%32.86%14.93%-12.33%2.90%-18.38%-58.52%-3.77%3.30%22.39%28.30%25.42%22.88%1866.67%-159.34%105.08%55.56%------0.00%-34.78%-133.00%-20.83%61.90%58.82%-75.00%26.25%-5.00%-1100.00%27.45%-3.23%-65.52%---
Timing--Pre-marketPre-marketPre-market-After-hoursAfter-hours---After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours-After-hoursPre-marketAfter-hours---

Key Statistics & Ratios

Market Cap6.08M
Enterprise Value1.41M
Trailing P/E0.00
Forward P/E46.08
PEG Ratio1.08
Price / Sales0.28
Price / Book0.91
EPS-1.22
Book Value1.72
Revenue (TTM)21.92M
Gross Profit (TTM)8.53M
EBITDA-1.27M
Profit Margin-10.33%
Operating Margin-0.62%
Return on Equity-42.52%
Return on Assets-5.37%
Shares Outstanding4.79M
Shares Float4.77M
Beta1.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 12.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
2.31%
Insiders
0.42%
Retail / Other
97.27%

Top Institutional Holders

  • Geode Capital Management, LLC
    19.94K0.42%
  • Vanguard Capital Management, LLC
    18.79K0.39%
  • DRW Securities, LLC
    12.02K0.25%
  • Mckinley Carter Wealth Services Inc
    11.19K0.23%
  • Global Retirement Partners, LLC.
    2.55K0.05%
  • Morgan Stanley - Brokerage Accounts
    2.00K0.04%
  • Citigroup Inc
    1.43K0.03%
  • Tower Research Capital LLC
    1.23K0.03%
  • Advisor Group Holdings, Inc.
    5000.01%
  • JPMorgan Chase & Co
    1230.00%
  • BlackRock Inc
    1130.00%
  • Vanguard Fiduciary Trust Co
    1000.00%
  • U.S. Bancorp
    250.00%
  • HARBOUR INVESTMENTS, INC.
    150.00%
  • UBS Group AG
    60.00%
  • Quaker Wealth Management, LLC
    30.00%
  • Caitong International Asset Management Co., Limited.
    10.00%

Top Fund Holders

  • Fidelity Extended Market Index
    20.91K0.44%
  • Fidelity Total Market Index
    2.53K0.05%
  • Fidelity Series Total Market Index
    2.31K0.05%

Stock Splits

  • Aug 30, 20241:20
  • Jun 20, 20191:9
  • Jun 27, 20161:5
  • Apr 1, 20131:7